Samoila G, Twine C P, Williams I M
Cardiff and Vale University Health Board , UK.
Aneurin Bevan University Health Board , UK.
Ann R Coll Surg Engl. 2018 Feb;100(2):83-91. doi: 10.1308/rcsann.2017.0154.
Introduction Paget-Schroetter syndrome is a rare effort thrombosis of the axillary-subclavian vein, mainly occurring in young male patients. Current management involves immediate catheter directed thrombolysis, followed by surgical decompression of the subclavian vein. This has been invariably performed using a transaxillary or supraclavicular approach. However, the subclavian vein crosses the first rib anteriorly just behind the manubrium and can also be accessed via an infraclavicular incision. Methods MEDLINE and Embase™ were searched for all studies on outcomes in patients undergoing infraclavicular first rib resection for treatment of Paget-Schroetter syndrome. Measured outcomes included freedom from reintervention, secondary patency and symptom resolution. Studies on neurogenic, arterial and iatrogenic venous thoracic outlet syndrome were not included. Findings Six studies (involving 268 patients) were eligible. The overall secondary venous patency rate was 98.5%. There was freedom from reintervention in 89.9% of cases and among those patients with reocclusion, 84.0% had chronic thrombosis (symptom duration >14 days), with 76.2% having a venous segment stenosis of >2cm. Only 3 of the 27 patients remained occluded despite reintervention. The infraclavicular approach provides excellent exposure to the subclavian vein and allows reconstruction when required. Moreover, this approach enables complete resection of the extrinsic compression that precipitated the initial thrombotic event, with excellent long-term patency rates. In conclusion, the infraclavicular route may have significant advantages compared with the transaxillary or supraclavicular approaches for successful and durable treatment of Paget-Schroetter syndrome.
引言
佩吉特-施罗特综合征是一种罕见的腋-锁骨下静脉用力性血栓形成,主要发生于年轻男性患者。目前的治疗方法包括立即进行导管定向溶栓,随后对锁骨下静脉进行手术减压。这一操作一直以来都是通过经腋窝或锁骨上入路进行的。然而,锁骨下静脉在胸骨柄后方从前穿过第一肋,也可通过锁骨下入路进行手术。
方法
检索MEDLINE和Embase™数据库,查找所有关于采用锁骨下入路切除第一肋治疗佩吉特-施罗特综合征患者的预后研究。测量的预后指标包括无需再次干预、二级通畅率和症状缓解情况。不包括关于神经源性、动脉性和医源性胸廓出口综合征的研究。
结果
六项研究(涉及268例患者)符合纳入标准。总体二级静脉通畅率为98.5%。89.9%的病例无需再次干预,在那些再闭塞的患者中,84.0%患有慢性血栓形成(症状持续时间>14天),76.2%的患者静脉段狭窄>2cm。27例患者中只有3例尽管进行了再次干预仍处于闭塞状态。锁骨下入路能很好地暴露锁骨下静脉,并在需要时允许进行重建。此外,该入路能够完全切除引发初始血栓形成事件的外部压迫因素,长期通畅率良好。总之,与经腋窝或锁骨上入路相比,锁骨下入路在成功且持久地治疗佩吉特-施罗特综合征方面可能具有显著优势。